Global Endowment Management, LP Biogen Inc. Transaction History

Global Endowment Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 12, 2020	SELL	$220.06 - $304.07 $213,678 - $295,251	-971 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$217.44 - $243.88 $1.68 Million - $1.88 Million	-7,719 Reduced 88.83%	971 $226,000
Q2 2019 Aug 12, 2019	BUY	$219.29 - $241.72 $1.67 Million - $1.84 Million	7,600 Added 697.25%	8,690 $2.03 Million
Q4 2018 Feb 12, 2019	SELL	$278.5 - $352.75 $5.29 Million - $6.7 Million	-18,990 Reduced 94.57%	1,090 $328,000
Q3 2018 Nov 09, 2018	SELL	$293.51 - $383.83 $587,020 - $767,660	-2,000 Reduced 9.06%	20,080 $7.1 Million

Q2 2018 Aug 10, 2018	BUY	$257.52 - $306.91 $1.44 Million - $1.72 Million	5,600 Added 33.98%	22,080 $6.41 Million
Q1 2018 May 11, 2018	BUY	$260.13 - $367.91 $4.03 Million - $5.7 Million	15,500 Added 1581.63%	16,480 $4.51 Million
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $275,527 - $323,096	980	980 $307,000

1,047

126M

1.37M

1.35M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $33.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Global Endowment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Global Endowment Management, LP with notifications on news.